SCHEMBL20119912

SCHEMBL20119912

CNCCn1ccc2c(NCc3ccco3)nc(Cl)nc21

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
KMT2A Q03164 5/20 0.45
HRH4 Q9H3N8 3/20 0.43
LMNA P02545 5/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 5/20 0.41
MEN1 O00255 3/20 0.41
HTT P42858 3/20 0.41
MAPK1 P28482 2/20 0.41
PDE5A O76074 2/20 0.41
BLM P54132 1/20 0.41
REN P00797 1/20 0.41
CHRM4 P08173 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALDH1A1 P00352 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119403 0.88 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119446 0.87 MTNR1A (0.45) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119724 0.87 KMT2A (0.52) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119634 0.86 LMNA (0.45) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119351 0.86 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119378 0.86 KMT2A (0.51) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119876 0.84 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119774 0.82 SMN1; SMN2 (0.43) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL20119712 0.82 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AHRH4LMNAKDM4E
SCHEMBL22403784 0.81 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AHRH4LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HRH4 4263/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HRH4 4263/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HRH4 4263/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HRH4 4263/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HRH4 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.